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the single nucleotide exchange16934T>A is associated with dif-
ferences in TLR2 functionality. Of note, a search for possible tran-
scription factor binding sites with TFSEARCH (http://
www.cbrc.jp/research/db/TFSEARCH.html) did not provide evi-
dence that the 16934T>A mutation itself leads to differences
in TLR2 gene expression. In contrast, the number of GT repeats
in intron 2 of the TLR2 gene has been shown to be linked with dif-
ferential cytokine responses [1]. Thus, the difference in
16934A>T allele frequencies between patients with and with-
out SBP is more likely to reﬂect association with the numbers
of TLR2 GT repeats rather than an effect of the SNP itself. Since
Bruns et al. did not report on the TLR2 GT repeat polymorphism,
we do not know if a similar association also exists in their
patients’ sample. In particular, alleles with long GT repeats
(>20) – the risk factor for SBP in our study – are found more often
in association with both the homozygous 16934T/T and the het-
erozygous 16934A/T genotypes. Interestingly, the distribution
of alleles shown by Bruns and co-workers indicates SBP to have
occurred most often among heterozygous carriers of the
16934A>T polymorphism. This particular feature and the over-
all small number of observed SBP episodes (25/119 = 21%) may
have resulted in the fact that 16934T/T homozygosity was not
conﬁrmed by the work of Bruns and co-workers.
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We now conﬁrm the negative association of rs12979860 CC
with histologically-determined steatosis (111/184, 60% vs. 266/
383, 69%; p = 0.036) and steatosis grade >1 (17/184, 9% vs. 70/
383 18%; p = 0.0059) in 567 naïve, consecutive, non genotype-3
patients from referral centers in Milan and Vienna, without exces-
sive alcohol intake (>i.e. 60/40 g/day for M/F), HBsAg positivity,
and HIV infection. Sixty-ﬁve percent of patients were genotype-
1, and 20% had cirrhosis. A similar trendwas observed for all geno-
types. Importantly, as shown in Table 1, the association between
IL28B genotype and steatosiswas independent of acquired risk fac-
tors, and of the PNPLA3 GG genotype. Interestingly however, the
rs12979860 CC genotype protected form steatosis in patients posi-
tive, but not in those negative for the PNPLA3 G variant at risk (49/
78, 63% vs. 144/187, 77%, p = 0.022 and 62/106, 58% vs. 74/196,
62%, p = 0.52, respectively). Therefore, data suggest the possibility
that an interaction occurs between IL28B and PNPLA3 genotypes in
the pathogenesis of steatosis in CHC non genotype-3 patients.
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Reply to: ‘‘Interaction between IL28B and PNPLA3 genotypes
in the pathogenesis of steatosis in chronic hepatitis C
non genotype-3 patients’’
To the Editor:
We thank Dr. Valenti et al. for raising an additional point that
PNPLA3 might be associated with steatosis in the setting of HCV
infection after controlling for IL28B [1]. They demonstrate in their
cohort of 567 treatment naïve patients that both IL28B
(rs12979860) and PNPLA3 (rs738409) may contribute to steato-
sis. Furthermore, in their study the beneﬁcial effect of IL28B
was limited to the patients without the PNPLA3 risk allele ‘‘G’’
as rs738409. A role of PNPLA3 GG genotype for steatosis in HCV
infected patients has been observed in several studies, especially
when excluding genotype 3 patients [2–5]. In the Duke cohort,
we did not ﬁnd a signiﬁcant difference for steatosis in relation
to PNPLA3, (25/52 vs. 67/127, p = 0.623). However, in the European
cohort, the rs738409 SNP was used instead of SNP rs2281135.
The SNP rs2281135 is considered a tagging SNP (rs2281135) for
the likely causal SNP (rs738409) within the PNPLA3 region. Thus,
as we had a tagging SNP (rs2281135) for the likely causal SNP
(rs738409) within the PNPLA3 region only for the Duke cohort,
we cannot rule out that the lack of a signiﬁcant difference is
due to the lack of accuracy of a surrogate SNP. Interestingly
though, when grouped according to PNPLA3 rs2281135 GG vs.
non-GG, the role of IL28B remained signiﬁcant in the PNPLA3
rs2281135 GG patients only (p = 0.002), while it was only a trend
in the non-GG patients (p = 0.46).
Evaluation of the combined effect of IL28B and PNPLA3 geno-
types on treatment outcomes may permit to discriminate
whether steatosis has indeed a causal role in determining resis-
tance to antivirals, or the association is an epiphenomenon due
to the confounding association of steatosis with IL28B
rs12979860 CC, as suggested by Tillmann et al. [4].
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Table 1. Independent predictors of steatosis in 567 non genotype-3 CHC
patients.
OR 95% CI p
Age (yr) 1.04 1.02-1.05 <0.0001
BMI (kg/m2) 1.20 1.13-1.28 <0.0001
PNPLA3 rs738409 GG 3.36 1.50-8.70 0.0025
IL28B rs12979860 CC 0.57 0.38-0.85 0.0060
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